Back to all assets

Zoetis ZTS

equity

Price History

$28.94$100.64$172.33$244.03
2013-02 · DCA start$33.45

Time underwater

How far below its previous all-time high the price sat, each month. 0% means a new high.

-70.6%-47.0%-23.5%0.0%
2013-022026-08 · -69.9%

Worst drawdown: −71%, peaking Dec 2021 and bottoming Jun 2026 — still unrecovered after 56 months.

DCA Backtest

Invested
$16,300
Value today
$16,056
Return
-1.5%
Months invested
163

Scenarios

Inflation — the same contributions merely keeping pace with CPI would be $20,400 today, so the real (inflation-adjusted) return is -21.3%.

Lump sum instead — $16,300 all at once in Feb 2013: $35,836 (+119.9%) — lump sum came out ahead.

Worst timing — same monthly amount started at the all-time high (Dec 2021): $2,779 on $5,700 invested (-51.3%).

⚠ Price returns only — dividends are not included. This understates the true return of dividend-paying shares, and any comparison against crypto (which pays no dividends) is biased against equities by roughly the dividend yield, compounded.

If this saved you a spreadsheet — buy me a coffee.

Every start month at once

Each cell is the return-to-date of £/$/€100-a-month DCA started that month. Click a cell to load it in the backtest above. The ringed cell is the all-time-high start — the worst timing scenario.

JFMAMJJASOND
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Legend:−50%−20%0%+50%+200%+1000%worst timing (ATH)Selected 2013-02: -1.5%

About Zoetis

Zoetis Inc. (/zō-EH-tis/) is an American drug company, the world's largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the world's largest drug maker, but with Pfizer's spinoff of its 83% interest in the firm it is now a completely independent company. The company directly markets its products in approximately 45 countries, and sells them in more than 100 countries. Operations outside the United States accounted for 50% of the total revenue. (Wikipedia)

It's a listed company categorised under health care and pharmaceuticals, with a market cap of about $30.4B.

It rates Medium-High Risk at 2.5/5, meaning real but ordinary risk — the kind most mainstream assets carry, with some factors scoring poorly.

What pushes the score up: leverage / financial (4.0/5) and market / volatility (3.0/5).

Scoring well: earnings quality at 1.0/5.

Not yet researched: concentration, governance. These are excluded from the score rather than guessed, so the real risk may be higher than what’s shown.

Ratings summarise sourced facts against fixed rules — not investment advice, and no substitute for your own diligence.

Risk Profile

Medium-High Risk(2.5/5)80% rated

How these ratings work

Market / Volatility3.0/5 · weight 20%
  • Annualised volatility (3yr)3/532.3
  • Max drawdown from ATH4/570.6
  • Beta vs S&P 5002/50.73
Liquidity1.0/5 · weight 15%
  • Avg daily $ volume1/5567.8m
  • Float % of shares outstandingnot yet researched
Leverage / Financial4.0/5 · weight 20%
  • Debt / equity4/52.9
  • Interest coverage (EBIT / interest)not yet researched
Earnings Quality1.0/5 · weight 15%
  • 3yr EPS volatility1/51.5
Concentrationunrated · weight 10%
  • Largest customer, % of revenuenot yet researched
  • Geographic revenue concentrationnot yet researched
Governanceunrated · weight 10%
  • Board independence %not yet researched
  • Share structurenot yet researched
  • Litigation / audit historynot yet researched
Sector / Regulatory3.0/5 · weight 10%
  • Sector regulatory exposure3/5elevated

Linked Assets

Same sector, or return-correlated — worth knowing what else might move if this one does.